NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/14/2023
Back to search
Official data from USPTO
LARIMAR
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
46
Latest update
02/14/2023
Trademark type
Word
Nice classes
5, 42
Filing date
05/24/2019
Registration date
02/14/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/14/2023
Last transaction
02/14/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2022-10-00
First use in commerce
2022-10-00
Drawing code
4
Owner type
03
Owner location
BALA CYNWYD, PA
Examiner
BODRI, KRISTIN
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
LARIMAR THERAPEUTICS, INC.
Chondrial Therapeutics Inc.
Representatives
Keith Toms, Esq. MCCARTER & ENGLISH, LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of mitochondrial disorders; Pharmaceutical preparations and substances for treatment of genetic diseases; pharmaceutical preparations for the treatment of diseases or dysfunction of the mitochondria; pharmaceutical preparations featuring cell penetrating peptides for use in the treatment of genetic disorders; pharmaceuticals that treat genetic diseases by use of carrier proteins; pharmaceutical preparations for the treatment of ataxia; pharmaceutical preparations for the treatment of Friedreich's Ataxia; pharmaceutical preparations for protein replacement therapy
Class 42
Pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; research in the field of pharmaceuticals and drugs; conducting genomic analysispre-clinical studies and clinical trials for others in the field of pharmaceutical preparations for treatment of diseases
Publications
History of USPTO decisions and trademark events.
46 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
02/14/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/07/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/06/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
12/16/2022
IUAF
USE AMENDMENT FILED
12/13/2022
EISU
TEAS STATEMENT OF USE RECEIVED
12/13/2022
DOCK
ASSIGNED TO EXAMINER
12/13/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/31/2022
EX5G
SOU EXTENSION 5 GRANTED
08/30/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/29/2022
EXT5
SOU EXTENSION 5 FILED
06/09/2022
EEXT
SOU TEAS EXTENSION RECEIVED
06/09/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/18/2021
EX4G
SOU EXTENSION 4 GRANTED
12/16/2021
EXT4
SOU EXTENSION 4 FILED
12/16/2021
EEXT
SOU TEAS EXTENSION RECEIVED
12/16/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/22/2021
EX3G
SOU EXTENSION 3 GRANTED
06/21/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/16/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
06/14/2021
EXT3
SOU EXTENSION 3 FILED
06/07/2021
EEXT
SOU TEAS EXTENSION RECEIVED
06/07/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/03/2020
EX2G
SOU EXTENSION 2 GRANTED
12/01/2020
EXT2
SOU EXTENSION 2 FILED
12/01/2020
EEXT
SOU TEAS EXTENSION RECEIVED
12/01/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/28/2020
EX1G
SOU EXTENSION 1 GRANTED
04/24/2020
EXT1
SOU EXTENSION 1 FILED
04/24/2020
EEXT
SOU TEAS EXTENSION RECEIVED
04/24/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/17/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/22/2019
PUBO
PUBLISHED FOR OPPOSITION
10/22/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/02/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/17/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
09/17/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/17/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
09/17/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/17/2019
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
08/20/2019
GPRA
PRIORITY ACTION E-MAILED
08/20/2019
CPRA
PRIORITY ACTION WRITTEN
08/20/2019
DOCK
ASSIGNED TO EXAMINER
08/13/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/10/2019
NWAP
NEW APPLICATION ENTERED
05/28/2019
Continuous trademark protection
Get notified about every new filing that threatens LARIMAR or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.